Casdin Capital’s Bristol-Myers Squibb BMY Stock Holding History

Casdin Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-21,000	Closed	-$1.54M	–	27
2016 Q2	$1.54M	Hold	21,000	–	–	1.54%	23
2016 Q1	$1.34M	Sell	21,000 -11,164	-35%	-$704K	1.54%	20
2015 Q4	$2.21M	Buy	+32,164	New	+$2.13M	1.96%	18

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Casdin Capital's BMY Position: Q3 2016 in Review

Casdin Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2016, closing a stake of 21,000 shares — an estimated $1.54M sold.

Casdin Capital first reported a position in BMY in Q4 2015 and held it in 3 quarters. The position peaked at $2.21M in Q4 2015. 1,522 funds tracked by Wall St. Rank hold BMY as of Q3 2016.

Casdin Capital reported no remaining Bristol-Myers Squibb position as of Q3 2016 after selling out during the quarter.
Casdin Capital sold 21,000 Bristol-Myers Squibb shares in Q3 2016, an estimated $1.54M.
Casdin Capital first reported a position in Bristol-Myers Squibb in Q4 2015 and held it in 3 quarters.
Casdin Capital's Bristol-Myers Squibb position peaked at $2.21M in Q4 2015.
1,522 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2016.

Based on Casdin Capital's 13F filing for Q3 2016, filed 14 Nov 2016.